Settlement Agreement, Presentation of Trial Results, and Stock Price Update - Research Report on Johnson & Johnson, Mettler-Toledo, Galena Biopharma, Dendreon, and Amedisys Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 25, 2013 NEW YORK, November 25, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Mettler-Toledo International, Inc. (NYSE: MTD), Galena Biopharma, Inc. (NASDAQ: GALE), Dendreon Corp. (NASDAQ: DNDN), and Amedisys Inc. (NASDAQ: AMED). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Johnson & Johnson Research Report On November 19, 2013, Johnson & Johnson reported that DePuy Orthopaedics, Inc. (DePuy), a part of its DePuy Synthes Companies, and the Court-appointed committee of lawyers representing ASR™ Hip System plaintiffs has entered into a settlement agreement to compensate eligible ASR patients in the United States who underwent surgery to replace their ASR hip, as of August 31, 2013. Andrew Ekdahl, Worldwide President, DePuy Synthes Joint Reconstruction, commented, "We are committed to the well-being of ASR patients, as demonstrated by the voluntary recall and the program providing support for recall-related care. The U.S. settlement program provides compensation for eligible patients without the delay and uncertainty of protracted litigation. DePuy remains committed to our purpose of advancing innovative treatment options to serve those who need joint replacement surgery." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/07a8_JNJ -- Mettler-Toledo International, Inc. Research Report On November 20, 2013, Mettler-Toledo International, Inc.'s (Mettler-Toledo) stock increased 0.02%, ending the day's session at $248.40. Over the previous three trading sessions, shares of Mettler-Toledo increased 0.37%, compared to the Dow Jones Industrial Average Index, which increased 0.38% during the same period. The Full Research Report on Mettler-Toledo International, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/ac69_MTD -- Galena Biopharma, Inc. Research Report On November 11, 2013, Galena Biopharma, Inc. (Galena Biopharma) announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) Conference 2013 from November 7-10, 2013, in National Harbor, Maryland. According to the Company, the data presented are the results of the Phase 1 portion of the trial for the Folate Binding Protein (FBP) vaccine. Mark J. Ahn, President and CEO of Galena Biopharma, commented, "We are encouraged by the initial results of our Phase 1 trial with the FBP vaccine, showing that it is well-tolerated and demonstrated promising immune responses in high risk gynecological cancers. As a result, we are moving forward with the Phase 2a component which will be initiated by year end and will include the enrollment of additional patients at the optimal dose as well implementing a booster regimen." The Full Research Report on Galena Biopharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/cad6_GALE -- Dendreon Corp. Research Report On November 20, 2013, Dendreon Corp.'s (Dendreon) stock declined 4.07%, ending the day's session at $2.83. Over the previous three trading sessions, shares of Dendreon increased 11.42%, compared to the Nasdaq Composite Index, which declined 1.62% during the same period. The Full Research Report on Dendreon Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/de0c_DNDN -- Amedisys Inc. Research Report On November 20, 2013, Amedisys Inc.'s (Amedisys) stock declined 1.79%, ending the day's session at $14.30. Over the previous three trading sessions, shares of Amedisys declined 0.35%, compared to the Nasdaq Composite Index, which declined 1.62% during the same period. The Full Research Report on Amedisys Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/56b5_AMED ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Settlement Agreement, Presentation of Trial Results, and Stock Price Update - Research Report on Johnson & Johnson, Mettler
Press spacebar to pause and continue. Press esc to stop.